Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.
Pharmaceutical firm Eli Lilly is in line for an exit from US-based liver disease drug developer Terns Pharmaceuticals, which has filed for a $100m initial public offering. Terns is working on small-molecule drugs to treat chronic liver diseases including non-alcoholic steatohepatitis (NASH). Part of the IPO proceeds will support the completion of a phase 2a…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.